ERBB2 and cancer: This is perhaps the case as prior lines in those with TNBC will have been chemotherapy regimens whereas in those with ER + /HER2- and HER2 + cancers, endocrine therapies and HER2-targeted agents will have contributed significantly with potentially non-overlapping mechanisms of resistance.